BioE vaccine prequalified by WHO

Published: 23rd July 2013 08:59 AM  |   Last Updated: 23rd July 2013 08:59 AM   |  A+A-

Biological E (BioE) and European biotech company Valneva SE on Monday said the World Health Organization (WHO) has  pre-qualified its  Japanese Encephalitis vaccine for global use in adults. The company expects  that the paediatric indication will also be prequalified by the end of 2013.

The WHO prequalification was a key step for distribution of the vaccine in developing countries. “We are happy that our JE vaccine is the first ever WHO prequalified vaccine. It is an extremely important achievement for the vaccines community as our vaccine’s prequalification is well in time to support GAVI’s plans of introducing the JE vaccine in several developing countries,” said Mahima Datla, MD, BioE.

BioE and Valneva have joined hands in partnership in 2005 for the development and commercialization of a Japanese Encephalitis vaccine for endemic regions, based on Valneva’s JEV technology. The vaccine is being marketed in India under the trade-name JEEV and commercialization in other JE-endemic countries is planned.

Stay up to date on all the latest Andhra Pradesh news with The New Indian Express App. Download now


Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on are those of the comment writers alone. They do not represent the views or opinions of or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp